<DOC>
	<DOCNO>NCT00359190</DOCNO>
	<brief_summary>This study examine inhibition ErbB1 ErbB2 phosphorylation downstream mediator tumor cell growth survival tumor tissue treatment-naive breast cancer patient three dose schedule lapatinib .</brief_summary>
	<brief_title>Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Clinical lab within acceptable range . A histologically confirm , treatmentnaive , breast tumor measure 1 cm great readily biopsied . At least 18 year age . Females must meet certain criterion specify protocol . Ability swallow retain oral medication . Ability follow understand direction . Exclusion criterion : Female pregnant lactating . Medically unfit doctor result medical interview physicals . Received treatment investigational drug within 4 week study start . Currently receive treatment prohibit med list protocol . Had major surgery previous 2 week . Had prior radiation therapy chest treat incidence breast cancer . Hypersensitivity reaction idiosyncrasy drug chemically relate study med . Has malabsorption syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>breast cancer</keyword>
	<keyword>treatment-naive</keyword>
</DOC>